Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for Hereditary Spastic Paraplegia Type 5
NCT04101643Phase 2Unknown
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Sep 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of evolocumab in hereditary spastic paraplegia type 5 (SPG5), sponsored by The First Hospital of Fujian Medical University. Status: unknown.
02
Drugs
evolocumab
03
Conditions
hereditary spastic paraplegia type 5 (SPG5)
Beyond the preview
Go deeper on NCT04101643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101643.